CB1 Receptor

The CB1 receptor is the most abundant G-protein-coupled receptor in the mammalian brain, with expression densities far exceeding most other neurotransmitter receptors. CB1 was discovered in 1988 during research into how THC produces psychoactive effects, and the receptor was named for its high binding affinity for cannabinoids. Distribution: CB1 receptors are concentrated in specific brain regions corresponding to their functional roles — hippocampus (memory and learning, explaining THC-induced short-term memory effects), basal ganglia and cerebellum (motor control, explaining THC-induced impairment of fine coordination), hypothalamus (appetite regulation, explaining the "munchies"), prefrontal cortex (executive function and decision-making, explaining altered judgment), amygdala (emotional processing, explaining anxiety/euphoria modulation), spinal cord (pain signaling, explaining analgesic effects). CB1 receptors are notably ABSENT from the brainstem regions controlling vital functions (respiration, heart rate), which is why cannabis cannot cause fatal overdose unlike opioids that depress the brainstem. Mechanism: CB1 is a presynaptic receptor that, when activated, reduces the release of various neurotransmitters (glutamate, GABA, dopamine, serotonin, norepinephrine) at the synapse. This makes CB1 a "neuromodulator" rather than a direct neurotransmitter — it doesn't directly excite or inhibit neurons but instead controls how strongly other systems signal. THC mimics anandamide (the body's natural CB1 ligand) but binds with higher affinity and longer duration, producing exaggerated cannabinoid effects. CBD does NOT bind CB1 directly but acts as a negative allosteric modulator, reducing THC's binding effectiveness — this is why CBD reduces THC-induced anxiety. CB1 receptors downregulate with chronic THC exposure, leading to tolerance development; complete tolerance reset requires 14-30 days of cannabis abstinence (a "tolerance break").